

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/590,675
				Filing Date	August 25, 2006
				First Named Inventor	Nasser Chegini
				Art Unit	1645
				Examiner Name	
Sheet	1	of	6	Attorney Docket Number	UF-418C2XCZ1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-2001/0002393 A1	05-31-2001	Palmer et al.	All
	U2	US-2003/0032044 A1	02-13-2003	Chegini et al.	All
	U3	US-2003/0077589 A1	04-24-2003	Hess-Stumpp et al.	All
	U4	US-2004/0147574 A1	07-29-2004	Munchhof	All
	U	US-			
	U	US-			
	U	US-			
	U	US-			
	U	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	- Number ⁴ - Kind Code ⁵ (if known)			
	F1	WO	00/20642 A1	04-13-2000	Genzyme Corp; Univ. Fl.	All
	F2	WO	03/007685 A2	01-30-2003	Univ. of Florida	All
	F3	WO	2000/012497 A2	03-09-2000	Scios Inc.	All
	F4	WO	2004/021989 A2	03-18-2004	Biogen, Inc.	All
	F5	WO	2004/026307 A1	04-01-2004	Pfizer Prod. Inc.	All
	F6	WO	2004/026871 A1	04-01-2004	Eli Lilly & Comp.	All
	F					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/590,675	
			Filing Date	August 25, 2006	
			First Named Inventor	Nasser Chegini	
			Group Art Unit	1645	
			Examiner Name		
Sheet	2	of	6	Attorney Docket Number	UF-418C2XCZ1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	AHN, W.S. <i>et al.</i> "Targeted cellular process profiling approach for uterine leiomyoma using cDNA microarray, proteomics and gene ontology analysis" <i>Int J Exp Pathol</i> , 2003, pp. 267-79, Vol. 84.	
	R2	ARICI, A. and SOZEN, I. "Expression, menstrual cycle-dependent activation, and bimodal mitogenic effect of transforming growth factor- β 1 in human myometrium and leiomyoma" <i>Am J Obstet Gynecol</i> , 2003, pp. 76-83, Vol. 188.	
	R3	ARICI, A. and SOZEN, I. "Transforming growth factor- β 3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation" <i>Fertil Steril</i> , 2000, pp. 1006-1011, Vol. 73.	
	R4	BLOBE, G.C. "Role of transforming growth factor β in human disease" <i>et al. N Engl J Med</i> , 2000, pp. 1350-1358, Vol. 342.	
	R5	BUTTE, A. "The use and analysis of microarray data" <i>Nat Rev Drug Discov</i> , 2002 pp. 951-960, Vol. 1.	
	R6	BYFIELD, S.D. <i>et al.</i> , "SB-505124 is a selective inhibitor of transforming growth factor- β Type I receptors ALK4, ALK5, and ALK7" <i>Mol. Pharmacol.</i> , pp. 744-752, Vol. 65, No. 3.	
	R7	CARR, B.R. <i>et al.</i> "An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: A prospective, randomized, double blind, placebo-controlled, crossover trial" <i>J Clin Endocrinol Metab</i> , 1993, 76:1217-1223	
	R8	CHEGINI, N. <i>et al.</i> "Gonadotropin-releasing hormone (GnRH) and GnRH receptor gene expression in human myometrium and myometrial smooth muscle cells and interaction with ovarian steroids <i>in vitro</i> " <i>J Clin Endocrinol Metab</i> , 1996, pp. 3215-3221, Vol. 81, No. 9.	
	R9	CHEGINI, N. <i>et al.</i> "Gene expression profile of leiomyoma and myometrium and the effect of gonadotropin releasing hormone analogue therapy" <i>J Soc Gynecol Investig</i> , 2003, pp. 161-171, Vol. 10., No. 3.	
	R10	CHEGINI, N. and KORNBERG, L. "Gonadotropin releasing hormone analogue therapy alters signal transduction pathways involving mitogen-activated protein and focal adhesion kinases in leiomyoma" <i>J Soc Gynecol Investig.</i> , 2003, pp. 21-26, Vol. 10.	
	R11	CHEGINI, N. <i>et al.</i> "Regulation of transforming growth factor- β 1 expression by granulocyte macrophage-colony-stimulating factor in leiomyoma and myometrial smooth muscle cells" <i>J Clin Endocrinol Metab</i> , 1999, pp. 4138-4143, Vol. 84, No. 11.	
	R12	CHEGINI, N. <i>et al.</i> "The expression of Smads and transforming growth factor beta receptors in leiomyoma and myometrium and the effect of gonadotropin releasing hormone analogue therapy" <i>Mol Cell Endocrinol</i> , 2003, pp. 9-16, Vol. 209.	
	R13	CHEGINI, N. <i>et al.</i> "Effects of GnRH analogues, 'add-back' steroid therapy, antiestrogen and antiprogesterins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor- β expression" <i>Mol Hum Reprod</i> , 2002, pp. 1071-1078, Vol. 8, No. 12.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/590,675	
			Filing Date	August 25, 2006	
			First Named Inventor	Nasser Chegini	
			Group Art Unit	1645	
			Examiner Name		
Sheet	3	of	6	Attorney Docket Number	UF-418C2XCZ1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R14	CHWALISZ, K. <i>et al.</i> , "Therapeutic potential for the selective progesterone receptor modulator asoprisnil in the treatment of leiomyomata" <i>Semin. Reprod. Med.</i> , 2004, pp. 113-119, Vol. 22, No. 2.	
	R15	CLANCY, R.M. and BUYON, J.P. "Clearance of apoptotic cells: TGF- β in the balance between inflammation and fibrosis" <i>J Leukoc Biol</i> , 2003, pp. 959-960, Vol. 74.	
	R16	DEMANNO, D. <i>et al.</i> "Asoprisnil (J867): A selective progesterone receptor modulator for gynecological therapy" <i>Steroids</i> , 2003, pp. 1019-32, Vol. 68.	
	R17	DING, L. <i>et al.</i> "The expression of IL-13 and IL-15 in leiomyoma and myometrium and their influence on TGF- β and proteases expression in leiomyoma and myometrial smooth muscle cells and SKLM, leiomyosarcoma cell line" <i>J Soc Gynecol Invest</i> , 2004, 11(2 Suppl):319A, abstract no. 725.	
	R18	DING, L. <i>et al.</i> "Gonadotropin releasing hormone and transforming growth factor β activate mitogen-activated protein kinase/extracellularly regulated kinase and differentially regulate fibronectin, Type I collagen, and plasminogen activator inhibitor-1 expression in leiomyoma and myometrial smooth muscle cells" <i>J Clin Endocrinol Metab</i> , 2004, pp. 5549-5557, Vol. 89, No. 11.	
	R19	DOU, Q. <i>et al.</i> "Suppression of transforming growth factor- β (TGF β) and TGF β receptor messenger ribonucleic acid and protein expression in leiomyomata in women receiving gonadotropin-releasing hormone agonist therapy" <i>J Clin Endocrinol Metab</i> , 1996, pp. 3222-3230, Vol. 81, No. 9.	
	R20	DOU, Q. <i>et al.</i> "Differential expression of matrix metalloproteinases and their tissue inhibitors in leiomyomata: a mechanism for gonadotrophin releasing hormone agonist-induced tumour regression" <i>Mol Hum Reprod.</i> , 1997, pp. 1005-1014, Vol. 3, No. 11.	
	R21	DUBEY, R.K. <i>et al.</i> , "Tibolone and its metabolites induce antimitogenesis in human coronary artery smooth muscle cells: Role of estrogen, progesterone, and androgen receptors" <i>J. Clin. Endocrinol. Metab.</i> , 2004, pp. 852-859, Vol. 89, No. 2.	
	R22	ENGLUND <i>et al.</i> , "Sex steroid receptors in human myometrium and fibroids: Changes during the menstrual cycle and gonadotropin-releasing hormone treatment" <i>J. Clin. Endocrinol Metab.</i> , 1998, pp. 4092-4092, Vol. 83, No. 11.	
	R23	FLANDERS, K.C. "Smad3 as a mediator of the fibrotic response" <i>Int J Exp Pathol</i> , 2004, pp. 47-64, Vol. 85.	
	R24	FORNONI, A. <i>et al.</i> "Glucose induces clonal selection and reversible dinucleotide repeat expansion in mesangial cells isolated from glomerulosclerosis-prone mice" <i>Diabetes</i> , 2003, pp. 2594-2602, Vol. 52.	
	R25	FUKUHARA, K. <i>et al.</i> "Secreted frizzled related protein 1 is overexpressed in uterine leiomyomas, associated with a high estrogenic environment and unrelated to proliferative activity" <i>J Clin Endocrinol Metab</i> , 2002, pp. 1729-36, Vol. 87, No. 4.	
	R26	GELLIBERT, F. <i>et al.</i> , "Identification of 1,5-Naphthyridine derivatives as a novel series of potent and selective TGF- β Type I Receptor Inhibitors" <i>J. Med. Chem.</i> , 2004, pp. 4494-4506, Vol. 47.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/590,675
				Filing Date	August 25, 2006
				First Named Inventor	Nasser Chegini
				Group Art Unit	1645
				Examiner Name	
Sheet	4	of	6	Attorney Docket Number	UF-418C2XCZ1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R27	GUSTAVSSON, I. <i>et al.</i> "Tissue differences but limited sex steroid responsiveness of c-fos and c-jun in human fibroids and myometrium" <i>Mol Hum Reprod</i> , 2000, pp. 55-59, Vol. 6, No. 1.	
	R28	HJELMELAND, M.D. <i>et al.</i> , "SB-431542, a small molecule transforming growth factor- β -receptor antagonist, inhibits human glioma cell line proliferation and motility" <i>Mol. Cancer Ther.</i> , 2004, pp. 737-745, Vol. 3, No. 6.	
	R29	HJOBERG, J <i>et al.</i> "Induction of early growth-response factor 1 by platelet-derived growth factor in human airway smooth muscle" <i>Am J Physiol Lung Cell Mol Physiol</i> , 2004, pp. L817-825, Vol. 286.	
	R30	HODL, C. <i>et al.</i> , A novel, high-affinity, fluorescent progesterone receptor antagonist. Synthesis and in vitro studies" <i>Bioconj. Chem.</i> , 2004, pp. 359-365, Vol. 15, No. 2.	
	R31	HOFFMAN, P.J. <i>et al.</i> "Molecular characterization of uterine fibroids and its implication for underlying mechanisms of pathogenesis" <i>Fertility and Sterility</i> , 2004, pp. 639-649, 83, No. 3.	
	R32	KAKAR, S.S. <i>et al.</i> "Identification of distinct gene expression profiles associated with treatment of L β T2 cells with gonadotropin-releasing hormone agonist using microarray analysis" <i>Gene</i> , 2003, pp. 67-77, Vol. 308.	
	R33	LEE, B.S. and Nowak, R.A. "Human leiomyoma smooth muscle cells show increased expression of transforming growth factor- β 3 (TGF β 3) and altered responses to the antiproliferative effects of TGF β " <i>J Clin Endocrinol Metab</i> , 2001, pp. 913-920, Vol. 86.	
	R34	LEVENS, E. <i>et al.</i> "Differential Expression of fibromodulin and Abl-interactor 2 in leiomyoma and myometrium and regulation by gonadotropin releasing hormone analogue (GnRH α) therapy" <i>Fertil Steril</i> , 2004, 82(Suppl. 2):S88-S89.	
	R35	LIGON, A.H. and Morton, C.C. "Leiomyomata: Heritability and cytogenetic studies" <i>Hum Reprod Update</i> , 2001, pp. 8-14, Vol. 7, No. 1.	
	R36	LUO, X. <i>et al.</i> "Leiomyoma and myometrial gene expression profiles and their responses to gonadotropin-releasing hormone analog therapy" <i>Endocrinology</i> , 2005, pp. 1074-1096, Vol. 146, No. 3.	
	R37	LUO, X. <i>et al.</i> "Gene expression profiling of leiomyoma and myometrial smooth muscle cells in response to transforming growth factor- β " <i>Endocrinology</i> , 2005, pp. 1097-1118, Vol. 146, No. 3.	
	R38	MA, C. and CHEGINI, N. "Regulation of matrix metalloproteinases (MMPs) and their tissue inhibitors in human myometrial smooth muscle cells by TGF- β 1" <i>Mol Hum Reprod</i> , 1999, pp. 950-954, Vol. 5, No. 10.	
	R39	MARUO, T. <i>et al.</i> "Sex steroidal regulation of uterine leiomyoma growth and apoptosis" <i>Hum Reprod Update</i> , 2004, pp. 207-20, Vol. 10, No. 3.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/590,675	
			Filing Date	August 25, 2006	
			First Named Inventor	Nasser Chegini	
			Group Art Unit	1645	
			Examiner Name		
Sheet	5	of	6	Attorney Docket Number	UF-418C2XCZ1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R40	MIZUTANI, T. <i>et al.</i> "Suppression of cell proliferation and induction of apoptosis in uterine leiomyoma by gonadotropin-releasing hormone agonist (leuprolide acetate) <i>J Clin Endocrinol Metab</i> , 1998, pp. 1253-1255, Vol. 83, No. 4.	
	R41	OLMAN, M.A. and MATTHAY, M.A. "Transforming growth factor- β induces fibrosis in immune cell-depleted lungs" <i>Am J Physiol Lung Cell Mol Physiol</i> , 2003, pp. L522-6, Vol. 285.	
	R42	ORII, A. <i>et al.</i> "Altered post-translational modification of redox factor 1 protein in human uterine smooth muscle tumors" <i>J Clin Endocrinol Metab</i> , 2002, pp. 3754-9, Vol. 87, No. 8.	
	R43	PALOMBA, S. <i>et al.</i> "Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial" <i>Hum Reprod</i> , 2002, pp. 3213-3219, Vol. 17, No. 12.	
	R44	PAVLIDIS, P. "Using ANOVA for gene selection from microarray studies of the nervous system" <i>Methods</i> , 2003, pp. 282-289, Vol. 31.	
	R45	PETERSON, L.E. "Partitioning large-sample microarray-based gene expression profiles using principal components analysis" <i>Comput Methods Programs Biomed</i> , 2003, pp. 107-19, Vol. 70.	
	R46	QUADE, B.J. <i>et al.</i> "Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling" <i>Genes Chromosomes Cancer</i> , 2004, pp. 97-108, Vol. 40.	
	R47	SCHNAPER, H.W. <i>et al.</i> "TGF- β signal transduction and mesangial cell fibrogenesis" <i>Am J Physiol Renal Physiol</i> , 2003, pp. F243-252, Vol. 284.	
	R48	SENTURK, L.M. <i>et al.</i> "Interleukin 8 production and interleukin 8 receptor expression in human myometrium and leiomyoma" <i>Am J Obstet Gynecol</i> , 2001, pp. 559-566, Vol. 184.	
	R49	SKUBITZ <i>et al.</i> "Differential gene expression in uterine leiomyoma" <i>J. Lab. Clin. Med.</i> , 2003, pp. 297-308, Vol. 141.	
	R50	SOKOL, J.P. <i>et al.</i> "Cystatin C antagonizes transforming growth factor β signaling in normal and cancer cells" <i>Mol. Cancer Res.</i> , 2004, pp. 183-195, Vol. 2, No. 3.	
	R51	SOZEN, I. <i>et al.</i> "Expression and hormonal regulation of monocyte chemotactic protein-1 in myometrium and leiomyomata" <i>Fertil Steril</i> , 1998, pp. 1095-1102, Vol. 69, No. 6.	
	R52	STEINAUER, J. <i>et al.</i> "Systematic review of mifepristone for the treatment of uterine leiomyomata" <i>Obstet Gynecol</i> , 2004, pp. 1331-6, Vol. 103, No. 6.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/590,675
				Filing Date	August 25, 2006
				First Named Inventor	Nasser Chegini
				Group Art Unit	1645
				Examiner Name	
Sheet	6	of	6	Attorney Docket Number	UF-418C2XCZ1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R53	STEWART, E.A. <i>et al.</i> "Relative overexpression of collagen type-I and collagen type-III messenger ribonucleic acids by uterine leiomyomas during the proliferative phase of the menstrual cycle" <i>J Clin Endocrinol Metab</i> , 1994, pp. 900-6, Vol. 79, No. 3.	
	R54	TANG, X.M. <i>et al.</i> "The expression of transforming growth factor- β s and TGF- β receptor mRNA and protein and the effect of TGF- β s on human myometrial smooth muscle cells <i>in vitro</i> " <i>Mol Hum Reprod</i> , 1997, pp. 233-240, Vol. 3.	
	R55	THIEL, G. and CIBELLI, G. "Regulation of life and death by the zinc finger transcription factor Egr-1" <i>J Cell Physiol</i> , 2002, pp. 287-92, Vol. 193.	
	R56	TSIBRIS, J.C.M. <i>et al.</i> "Insights from gene arrays on the development and growth regulation of uterine leiomyomata" <i>Fertil Steril</i> , 2002, pp. 114-121, Vol. 78, No. 1.	
	R57	WATABE, T. <i>et al.</i> "TGF- β receptor kinase inhibitor enhances growth and integrity of embryonic stem cell-derived endothelial cells" <i>Journal of Cell Biology</i> , 2003, pp. 1303-1311, Vol. 163, No. 6.	
	R58	WANG, H. <i>et al.</i> "Distinctive proliferative phase differences in gene expression in human myometrium and leiomyomata" <i>Fertil Steril</i> , 2003, pp. 266-76, Vol. 80, No. 2.	
	R59	WESTON, G. <i>et al.</i> "Fibroids display an anti-angiogenic gene expression profile when compared with adjacent myometrium" <i>Mol Hum Reprod</i> , 2003, pp. 541-9, Vol. 9, No. 9.	
	R60	WU, X. <i>et al.</i> "Expression of basic fibroblast growth factor (bFGF), FGF receptor 1 and FGF receptor 2 in uterine leiomyomas and myometrium during the menstrual cycle, after menopause and GnRHa treatment" <i>Acta Obstet Gynecol Scand</i> , 2001, pp. 497-504, Vol. 80.	
	R61	XU, J. <i>et al.</i> "Differential expression, regulation, and induction of Smads, transforming growth factor- β signal transduction pathway in leiomyoma, and myometrial smooth muscle cells and alteration by gonadotropin-releasing hormone analog" <i>J Clin Endocrinol Metab</i> , 2003, pp. 1350-1361, Vol. 88, No. 3.	
	R62	YINGLING, J. <i>et al.</i> , "Development of TGF- β signaling inhibitors for cancer therapy" <i>Nat. Rev. Drug Discov.</i> , 2004, Dec.; pp. 1011-22, Vol. 3, No. 12.	
	R63	YOKOTA, H. <i>et al.</i> "CITED2-mediated regulation of MMP-1 and MMP-13 in human chondrocytes under flow shear" <i>J Biol Chem</i> , 2003, pp. 47275-47280, Vol. 278, No. 47.	
	R64	ZHAI, Y.L. <i>et al.</i> "Expression of cyclins and cyclin-dependent kinases in smooth muscle tumors of the uterus" <i>Int J Cancer</i> , 1999, pp. 244-50, Vol. 84.	
	R65		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.